Requirements for baculoviruses for clinical gene therapy applications

Baculoviruses have proven capacity for the production of recombinant proteins including virus-like particles and as viral vectors. Recent progress in preclinical studies suggest that baculoviruses have potential as new vectors for gene therapy but so far no clinical trials have been performed. To date, no specific guidelines for the use of baculoviruses as human gene therapy vectors exist but researchers can utilize existing guidelines made for other biological products. Because of the long history of research on baculoviruses, a lot of knowledge has been obtained that forms a good basis for the gene therapy development process. This article gives an overview of the current status of the application of baculovirus vectors in gene therapy and summarizes some of the challenges to overcome before the first clinical trials with baculoviruses can be accomplished.

Graphical abstractBaculoviruses Towards Gene Therapy Clinical Trials.Figure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Baculoviruses (BVs) are potential new vectors for gene therapy. ► No guidelines for the use of BVs as drugs exist. ► Existing guidelines for viral vectors already in clinical use can, however, be applied.